{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T23:59:24Z","timestamp":1794873564250,"version":"4.9.1"},"reference-count":159,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001412","name":"Council of Scientific and Industrial Research, India","doi-asserted-by":"publisher","award":["25WS(018)\/2023-24\/EMR-II\/ASPIRE"],"award-info":[{"award-number":["25WS(018)\/2023-24\/EMR-II\/ASPIRE"]}],"id":[{"id":"10.13039\/501100001412","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024586","name":"Human Resource Development Centre, Council of Scientific And Industrial Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024586","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002742","name":"Banaras Hindu University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002742","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001501","name":"University Grants Commission","doi-asserted-by":"publisher","award":["M-14\/84"],"award-info":[{"award-number":["M-14\/84"]}],"id":[{"id":"10.13039\/501100001501","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ijantimicag.2025.107640","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T06:20:48Z","timestamp":1759990848000},"page":"107640","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Overcoming antimicrobial resistance: Phage therapy as a promising solution to combat ESKAPE pathogens"],"prefix":"10.1016","volume":"66","author":[{"given":"Ritu Raj","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pandey Priya","family":"Arun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudhir Kumar","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6247-5242","authenticated-orcid":false,"given":"Meenakshi","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2025.107640_bib0001","unstructured":"World Health Organization (WHO), Antimicrobial resistance. 2020. Accessed December 1, 2024. https:\/\/www.who.int\/health-topics\/antimicrobial-resistance."},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0002","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","author":"Murray","year":"2022","journal-title":"The Lancet"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2016\/2475067","article-title":"Mechanisms of antimicrobial resistance in ESKAPE pathogens","volume":"2016","author":"Santajit","year":"2016","journal-title":"BioMed Res Int"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0004","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1586\/eri.13.12","article-title":"Clinical relevance of the ESKAPE pathogens","volume":"11","author":"Pendleton","year":"2013","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/595011","article-title":"Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America","volume":"48","author":"Boucher","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0006","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1128\/AAC.45.3.649-659.2001","article-title":"Bacteriophage therapy","volume":"45","author":"Sulakvelidze","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0007","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cell.2022.11.017","article-title":"Phage therapy: from biological mechanisms to future directions","volume":"186","author":"Strathdee","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0008","doi-asserted-by":"crossref","first-page":"e00018","DOI":"10.1128\/CMR.00066-18","article-title":"Phage therapy in the postantibiotic era","volume":"32","author":"Gordillo Altamirano","year":"2019","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0009","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.chom.2019.01.014","article-title":"Phage therapy: a renewed approach to combat antibiotic-resistant bacteria","volume":"25","author":"Kortright","year":"2019","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0010","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1007\/s11095-010-0313-5","article-title":"The phage therapy paradigm: pr\u00eat-\u00e0-porter or sur-mesure?","volume":"28","author":"Pirnay","year":"2011","journal-title":"Pharm Res"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0011","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.coviro.2021.11.005","article-title":"European regulatory aspects of phage therapy: magistral phage preparations","volume":"52","author":"Verbeken","year":"2022","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0012","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/emph\/eoy005","article-title":"Phage treatment of an aortic graft infected with Pseudomonas aeruginosa","volume":"2018","author":"Chan","year":"2018","journal-title":"Evol Med Public Health"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0013","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/s41591-019-0437-z","article-title":"Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus","volume":"25","author":"Dedrick","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0014","first-page":"3","article-title":"Phage therapy\u2014history from Twort and d\u2019Herelle through soviet experience to current approaches","volume":"83","author":"Chanishvili","year":"2012"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0015","first-page":"71","article-title":"Professor Giorgi Eliava and the Eliava Institute of Bacteriophage","volume":"3","author":"Chanishvili","year":"2022","journal-title":"PHAGE"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0016","first-page":"158","article-title":"Bacteriophage therapy as a potential management option for surgical wound infections","volume":"1","author":"Nadareishvili","year":"2020","journal-title":"Phage (New Rochelle)"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0017","first-page":"16","article-title":"Neat science in a messy world: the global impact of human behavior on phage therapy, past and present","volume":"1","author":"Jones","year":"2020","journal-title":"Phage (New Rochelle)"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0018","doi-asserted-by":"crossref","first-page":"870","DOI":"10.3390\/antibiotics13090870","article-title":"A comprehensive review on phage therapy and phage-based drug development","volume":"13","author":"Cui","year":"2024","journal-title":"Antibiotics"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0019","doi-asserted-by":"crossref","first-page":"396","DOI":"10.3390\/v10080396","article-title":"Enzymes and mechanisms employed by tailed bacteriophages to breach the bacterial cell barriers","volume":"10","author":"Fernandes","year":"2018","journal-title":"Viruses"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0020","doi-asserted-by":"crossref","first-page":"92","DOI":"10.12688\/f1000research.129080.1","article-title":"Hospital-acquired and ventilator-associated pneumonia caused by multidrug-resistant Gram-negative pathogens: understanding epidemiology, resistance patterns, and implications with COVID-19","volume":"12","author":"Hammoudi Halat","year":"2023","journal-title":"F1000Res"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0021","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1011363","article-title":"Induction mechanisms and strategies underlying interprophage competition during polylysogeny","volume":"19","author":"Silpe","year":"2023","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0022","doi-asserted-by":"crossref","first-page":"fnw015","DOI":"10.1093\/femsle\/fnw015","article-title":"The role of temperate bacteriophages in bacterial infection","volume":"363","author":"Davies","year":"2016","journal-title":"FEMS Microbiol Lett"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0023","doi-asserted-by":"crossref","first-page":"354","DOI":"10.4161\/viru.24498","article-title":"Importance of prophages to evolution and virulence of bacterial pathogens","volume":"4","author":"Fortier","year":"2013","journal-title":"Virulence"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0024","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.nmni.2017.08.005","article-title":"Molecular characterization of Panton-Valentine leukocidin (PVL) toxin-encoding phages from South India","volume":"20","author":"Balaji","year":"2017","journal-title":"New Microb New Infec"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.micpath.2023.106467","article-title":"Bacteriophage therapy against ESKAPE bacterial pathogens: current status, strategies, challenges, and future scope","volume":"186","author":"Kulshrestha","year":"2024","journal-title":"Microb Pathog"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0026","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3390\/ph15030291","article-title":"Characterization of novel lytic Myoviridae phage infecting multidrug-resistant Acinetobacter baumannii and synergistic antimicrobial efficacy between phage and Sacha inchi oil","volume":"15","author":"Wintachai","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0027","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3390\/antibiotics10020175","article-title":"Bacteriophage-derived depolymerases against bacterial biofilm","volume":"10","author":"Topka-Bielecka","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0028","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.ijmm.2010.04.002","article-title":"Bacteriophage endolysins: a novel anti-infective to control Gram-positive pathogens","volume":"300","author":"Fischetti","year":"2010","journal-title":"Int J Med Microbiol"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0029","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1073\/pnas.1714658115","article-title":"Cross-genus rebooting of custom-made, synthetic bacteriophage genomes in l-form bacteria","volume":"115","author":"Kilcher","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0030","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2174\/138920108785161604","article-title":"The use of phages for the removal of infectious biofilms","volume":"9","author":"Azeredo","year":"2008","journal-title":"CPB"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0031","doi-asserted-by":"crossref","first-page":"137","DOI":"10.33073\/pjm-2014-019","article-title":"Bacteriophages as an alternative strategy for fighting biofilm development","volume":"63","author":"Parasion","year":"2014","journal-title":"Pol J Microbiol"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e35666","article-title":"Genetically engineered phages and engineered phage-derived enzymes to destroy biofilms of antibiotics resistance bacteria","volume":"10","author":"Eghbalpoor","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0033","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.2217\/fmb.12.97","article-title":"Bacteriophage endolysins as novel antimicrobials","volume":"7","author":"Schmelcher","year":"2012","journal-title":"Future Microbiol"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0034","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.3389\/fmicb.2018.02517","article-title":"Phage-borne depolymerases decrease Klebsiella pneumoniae resistance to innate defense mechanisms","volume":"9","author":"Majkowska-Skrobek","year":"2018","journal-title":"Front Microbiol"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0035","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1042\/BST20150192","article-title":"From endolysins to Artilysin\u00aes: novel enzyme-based approaches to kill drug-resistant bacteria","volume":"44","author":"Gerstmans","year":"2016","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0036","doi-asserted-by":"crossref","first-page":"e00718","DOI":"10.1128\/AAC.00758-18","article-title":"Loss-of-function mutations in epaR confer resistance to \u03d5NPV1 infection in Enterococcus faecalis OG1RF","volume":"62","author":"Ho","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0037","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-01489-y","article-title":"Phage-antibiotic synergy to combat multidrug resistant strains of Gram-negative ESKAPE pathogens","volume":"15","author":"Morris","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0038","doi-asserted-by":"crossref","first-page":"e00424","DOI":"10.1128\/spectrum.00427-24","article-title":"Exploring synergistic and antagonistic interactions in phage-antibiotic combinations against ESKAPE pathogens","volume":"12","author":"Kunz Coyne","year":"2024","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0039","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-79924-9","article-title":"Phage cocktail amikacin combination as a potential therapy for bacteremia associated with carbapenemase producing colistin resistant Klebsiella pneumoniae","volume":"14","author":"Shein","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0040","first-page":"703","article-title":"Synergistic interaction between phage therapy and antibiotics clears Pseudomonas aeruginosa infection in endocarditis and reduces virulence","volume":"215","author":"Oechslin","year":"2016","journal-title":"INFDIS"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0041","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1080\/03009734.2019.1688433","article-title":"Pharmacological limitations of phage therapy","volume":"124","author":"Nilsson","year":"2019","journal-title":"Ups J Med Sci"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0042","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.123505","article-title":"Stability of bacteriophages in organic solvents for formulations","volume":"646","author":"Cao","year":"2023","journal-title":"Int J Pharm"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0043","doi-asserted-by":"crossref","first-page":"865","DOI":"10.3390\/v13050865","article-title":"Evaluation of the stability of bacteriophages in different solutions suitable for the production of magistral preparations in Belgium","volume":"13","author":"Duyvejonck","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0044","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1038\/s41598-024-54469-z","article-title":"Stability study in selected conditions and biofilm-reducing activity of phages active against drug-resistant Acinetobacter baumannii","volume":"14","author":"Bagi\u0144ska","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0045","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.3390\/cells12162057","article-title":"Stability considerations for bacteriophages in liquid formulations designed for nebulization","volume":"12","author":"Flint","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0046","doi-asserted-by":"crossref","first-page":"S370","DOI":"10.1093\/cid\/ciad555","article-title":"Advanced manufacturing, formulation and microencapsulation of therapeutic phages","volume":"77","author":"Malik","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0047","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.3389\/fmicb.2018.02172","article-title":"Nanoencapsulation of bacteriophages in liposomes prepared using microfluidic hydrodynamic flow focusing","volume":"9","author":"Cinquerrui","year":"2018","journal-title":"Front Microbiol"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0048","doi-asserted-by":"crossref","first-page":"4841","DOI":"10.1128\/AEM.00812-15","article-title":"Liposome-encapsulated bacteriophages for enhanced oral phage therapy against Salmonella spp","volume":"81","author":"Colom","year":"2015","journal-title":"Appl Environ Microbiol"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0049","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0153777","article-title":"Encapsulation of bacteriophage in liposome accentuates its entry in to macrophage and shields it from neutralizing antibodies","volume":"11","author":"Singla","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.125670","article-title":"Can bacteriophage be stabilised by lipid encapsulation when nebulised for inhalation delivery against Pseudomonas aeruginosa?","volume":"678","author":"Cao","year":"2025","journal-title":"Int J Pharm"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0051","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.jconrel.2024.09.049","article-title":"Phage-liposome nanoconjugates for orthopedic biofilm eradication","volume":"376","author":"Wang","year":"2024","journal-title":"J Control Release"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0052","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.124146","article-title":"Investigating the effectiveness of liposome-bacteriophage nanocomplex in killing Staphylococcus aureus using epithelial cell coculture models","volume":"657","author":"Li","year":"2024","journal-title":"Int J Pharm"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0053","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3390\/gels3010006","article-title":"Hydrogels for biomedical applications: their characteristics and the mechanisms behind them","volume":"3","author":"Chai","year":"2017","journal-title":"Gels"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0054","article-title":"Optimized dosing and delivery of bacteriophage therapy for wound infections","author":"Lin","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0055","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-99788-x","article-title":"In vitro, genomic characterization and pre-clinical evaluation of a new thermostable lytic Obolenskvirus phage formulated as a hydrogel against carbapenem-resistant Acinetobacter baumannii","volume":"15","author":"Sherif","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0056","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120850","article-title":"Hydrogel formulations containing non-ionic polymers for topical delivery of bacteriophages","volume":"605","author":"Chang","year":"2021","journal-title":"Int J Pharm"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0057","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jconrel.2025.01.091","article-title":"Potential of vB_Pa_ZCPS1 phage embedded in situ gelling formulations as an ocular delivery system to attenuate Pseudomonas aeruginosa keratitis in a rabbit model","volume":"380","author":"Abdelrahman","year":"2025","journal-title":"J Control Release"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0058","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jddst.2017.11.008","article-title":"Nanofiber in transmucosal drug delivery","volume":"43","author":"Deepak","year":"2018","journal-title":"J Drug Deliv Sci Technol"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0059","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.699054","article-title":"Nanotechnology based approaches in phage therapy: overcoming the pharmacological barriers","volume":"12","author":"Kaur","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0060","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1002\/jbm.b.33726","article-title":"Nanofiber mats composed of a chitosan-poly(d,l-lactic-co-glycolic acid)-poly(ethylene oxide) blend as a postoperative anti-adhesion agent: chitosan-PLGA-PEO blend nanofibers","volume":"105","author":"Ko","year":"2017","journal-title":"J Biomed Mater Res"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0061","doi-asserted-by":"crossref","first-page":"8330","DOI":"10.1038\/s41598-023-35364-5","article-title":"Bacteriophage-loaded functional nanofibers for treatment of P. aeruginosa and S. aureus wound infections","volume":"13","author":"Kielholz","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0062","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s12223-021-00946-1","article-title":"Phage therapy of wound-associated infections","volume":"67","author":"Zyman","year":"2022","journal-title":"Folia Microbiol (Praha)"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0063","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1128\/AAC.03786-14","article-title":"Bacteriophage-mediated control of a two-species biofilm formed by microorganisms causing catheter-associated urinary tract infections in an in vitro urinary catheter model","volume":"59","author":"Lehman","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0064","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2021.758392","article-title":"Prospects of inhaled phage therapy for combatting pulmonary infections","volume":"11","author":"Wang","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0065","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1089\/jamp.2021.0045","article-title":"Inhaled delivery of anti-pseudomonal phages to tackle respiratory infections caused by superbugs","volume":"35","author":"Chan","year":"2022","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0066","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1111\/bph.15526","article-title":"Inhaled bacteriophage therapy in a porcine model of pneumonia caused by Pseudomonas aeruginosa during mechanical ventilation","volume":"178","author":"Guillon","year":"2021","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0067","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0121-2022","article-title":"Phage therapy for pulmonary infections: lessons from clinical experiences and key considerations","volume":"31","author":"Mitropoulou","year":"2022","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0068","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.699054","article-title":"Nanotechnology based approaches in phage therapy: overcoming the pharmacological barriers","volume":"12","author":"Kaur","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0069","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1039\/D3MA00817G","article-title":"Bacteriophages as nanocarriers for targeted drug delivery and enhanced therapeutic effects","volume":"5","author":"Emencheta","year":"2024","journal-title":"Mater Adv"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0070","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.3390\/microorganisms11102389","article-title":"Efficacy of different encapsulation techniques on the viability and stability of diverse phage under simulated gastric conditions","volume":"11","author":"Dlamini","year":"2023","journal-title":"Microorganisms"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0071","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.3390\/pharmaceutics15061602","article-title":"Eudragit\u00ae FS microparticles containing bacteriophages, prepared by spray-drying for oral administration","volume":"15","author":"Tabare","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0072","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.3390\/pr11113146","article-title":"The development of oral solid dosage forms using the direct-compression tableting of spray-dried bacteriophages suitable for targeted delivery and controlled release","volume":"11","author":"Yazdi","year":"2023","journal-title":"Processes"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0073","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.121206","article-title":"Enteric-coated bacteriophage tablets for oral administration against gastrointestinal infections","volume":"609","author":"Khanal","year":"2021","journal-title":"Int J Pharm"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0074","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-51742-4","article-title":"Improved lyophilization conditions for long-term storage of bacteriophages","volume":"9","author":"Manohar","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0075","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.3390\/pharmaceutics15122792","article-title":"Freeze-drying of encapsulated bacteriophage T4 to obtain shelf-stable dry preparations for oral application","volume":"15","author":"\u015aliwka","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0076","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.125199","article-title":"The pharmaceutical quality of freeze-dried tablets containing therapeutic bacteriophages against Pseudomonas aeruginosa and Staphylococcus aureus","volume":"671","author":"Kom\u00e1rkov\u00e1","year":"2025","journal-title":"Int J Pharm"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0077","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.3390\/v16071155","article-title":"Development of stabilizing solution for long-term storage of bacteriophages at room temperature and application to control foodborne pathogens","volume":"16","author":"Kim","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0078","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12941-020-00389-5","article-title":"Bacteriophage therapy against Pseudomonas aeruginosa biofilms: a review","volume":"19","author":"Chegini","year":"2020","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0079","doi-asserted-by":"crossref","first-page":"377","DOI":"10.3390\/antibiotics9070377","article-title":"A review of topical phage therapy for chronically infected wounds and preparations for a randomized adaptive clinical trial evaluating topical phage therapy in chronically infected diabetic foot ulcers","volume":"9","author":"Duplessis","year":"2020","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0080","article-title":"Topically applied bacteriophage to control multi-drug resistant Pseudomonas aeruginosa-infected wounds in a New Zealand rabbit model","volume":"13","author":"Wang","year":"2022","journal-title":"Front Microbiol"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0081","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1038\/s41467-023-39370-z","article-title":"Personalized aerosolised bacteriophage treatment of a chronic lung infection due to multidrug-resistant Pseudomonas aeruginosa","volume":"14","author":"K\u00f6hler","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0082","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ejpb.2020.04.003","article-title":"High frequency acoustic nebulization for pulmonary delivery of antibiotic alternatives against Staphylococcus aureus","volume":"151","author":"Marqus","year":"2020","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0083","doi-asserted-by":"crossref","first-page":"602","DOI":"10.3390\/v15030602","article-title":"Administration of bacteriophages via nebulization during mechanical ventilation: in vitro study and lung deposition in macaques","volume":"15","author":"Le Guellec","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0084","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.3390\/cells12162057","article-title":"Stability considerations for bacteriophages in liquid formulations designed for nebulization","volume":"12","author":"Flint","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0085","doi-asserted-by":"crossref","first-page":"fnv242","DOI":"10.1093\/femsle\/fnv242","article-title":"Safety and efficacy of phage therapy via the intravenous route","volume":"363","author":"Speck","year":"2016","journal-title":"FEMS Microbiol Lett"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0086","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.3390\/antibiotics11101340","article-title":"The safety and efficacy of phage therapy: a systematic review of clinical and safety trials","volume":"11","author":"Stacey","year":"2022","journal-title":"Antibiotics"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0087","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s40560-024-00759-7","article-title":"Current status of bacteriophage therapy for severe bacterial infections","volume":"12","author":"Sawa","year":"2024","journal-title":"J Intensive Care"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0088","doi-asserted-by":"crossref","first-page":"279","DOI":"10.5694\/mja2.50355","article-title":"Phage therapy for severe bacterial infections: a narrative review","volume":"212","author":"Petrovic Fabijan","year":"2020","journal-title":"Med J Aust"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0089","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.3389\/fimmu.2017.01783","article-title":"The potential of phage therapy in sepsis","volume":"8","author":"G\u00f3rski","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0090","first-page":"638","article-title":"FDA approves bacteriophage trial","volume":"321","author":"Voelker","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0091","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.3390\/ijms23094577","article-title":"Phage therapy in the era of multidrug resistance in bacteria: a systematic review","volume":"23","author":"Aranaga","year":"2022","journal-title":"IJMS"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0092","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2022.907314","article-title":"Bacteriophage therapy for Staphylococcus aureus infections: a review of animal models, treatments, and clinical trials","volume":"12","author":"Plumet","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0093","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S1473-3099(24)00424-9","article-title":"Safety, pharmacokinetics, and pharmacodynamics of LBP-EC01, a CRISPR-Cas3-enhanced bacteriophage cocktail, in uncomplicated urinary tract infections due to Escherichia coli (ELIMINATE): the randomised, open-label, first part of a two-part phase 2 trial","volume":"24","author":"Kim","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0094","doi-asserted-by":"crossref","first-page":"lsad030","DOI":"10.1093\/jlb\/lsad030","article-title":"CRISPR-phage antibacterials to address the antibiotic resistance crisis: scientific, economic, and regulatory considerations","volume":"11","author":"Pacia","year":"2024","journal-title":"J Law Biosci"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0047742","article-title":"Pseudomonas aeruginosa keratitis in mice: effects of topical bacteriophage KPP12 administration","volume":"7","author":"Fukuda","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0096","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3390\/microorganisms11030545","article-title":"Biofilm-forming bacteria implicated in complex otitis media in children in the post-heptavalent pneumococcal conjugate vaccine (PCV7) era","volume":"11","author":"Ioannidis","year":"2023","journal-title":"Microorganisms"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0097","doi-asserted-by":"crossref","DOI":"10.1016\/j.vetmic.2024.110354","article-title":"Tailoring formulation for enhanced phage therapy in canine otitis externa: a cocktail approach targeting Pseudomonas aeruginosa and Staphylococcus pseudintermedius","volume":"301","author":"Kwon","year":"2025","journal-title":"Vet Microbiol"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0098","doi-asserted-by":"crossref","DOI":"10.1590\/s2175-97902018000117093","article-title":"Phage therapy: progress in pharmacokinetics","volume":"54","author":"Qadir","year":"2018","journal-title":"Braz J Pharm Sci"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0099","first-page":"112","article-title":"Phage therapy in the management of urinary tract infections: a comprehensive systematic review","volume":"4","author":"Al-Anany","year":"2023","journal-title":"PHAGE"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0100","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/nrmicro2761","article-title":"The rise of the Enterococcus: beyond vancomycin resistance","volume":"10","author":"Arias","year":"2012","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0101","doi-asserted-by":"crossref","first-page":"4166","DOI":"10.1128\/IAI.00711-10","article-title":"Enterococcal biofilm formation and virulence in an optimized murine model of foreign body-associated urinary tract infections","volume":"78","author":"Guiton","year":"2010","journal-title":"Infect Immun"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0102","article-title":"Transcriptome analysis reveals the molecular mechanism of \u03b3-linolenic acid eradicating the biofilm of vancomycin-resistant Enterococcus faecium","volume":"15","author":"Wei","year":"2025","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0103","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3390\/v15010179","article-title":"Enterococcus faecium bacteriophage vB_EfaH_163, a new member of the Herelleviridae family, reduces the mortality associated with an E. faecium vanR clinical isolate in a Galleria mellonella Animal Model","volume":"15","author":"Pradal","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0104","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2024.1416971","article-title":"A novel Enterococcus faecium phage EF-M80: unveiling the effects of hydrogel-encapsulated phage on wound infection healing","volume":"15","author":"Khazani Asforooshani","year":"2024","journal-title":"Front Microbiol"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0105","doi-asserted-by":"crossref","first-page":"6643","DOI":"10.1038\/s41598-019-43115-8","article-title":"Efficacy and safety assessment of two enterococci phages in an in vitro biofilm wound model","volume":"9","author":"Melo","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0106","first-page":"88","article-title":"Efficacy of Sb-1 bacteriophage in treating and preventing methicillin-resistant Staphylococcus aureus in a Galleria mellonella model of implant-associated infection","volume":"101-B","author":"Luca","year":"2019","journal-title":"Orthop Proc"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0107","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.jgar.2020.06.020","article-title":"In vitro and in vivo assessment of phage therapy against Staphylococcus aureus causing bovine mastitis","volume":"22","author":"Ngassam-Tchamba","year":"2020","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0108","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1086\/374001","article-title":"Experimental protection of mice against lethal Staphylococcus aureus infection by novel bacteriophage \u03c6MR11","volume":"187","author":"Matsuzaki","year":"2003","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0109","doi-asserted-by":"crossref","first-page":"935","DOI":"10.4014\/jmb.0909.09010","article-title":"Evidence to support the therapeutic potential of bacteriophage Kpn5 in burn wound infection caused by Klebsiella pneumoniae in BALB\/c mice","volume":"20","author":"Kumari","year":"2010","journal-title":"J Microbiol Biotechnol"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.virusres.2021.198348","article-title":"Identification and complete genome of lytic \u201cKp34likevirus\u201d phage vB_KpnP_Bp5 and therapeutic potency in the treatment of lethal Klebsiella pneumoniae infections in mice","volume":"297","author":"Zhang","year":"2021","journal-title":"Virus Res"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0111","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jgar.2019.09.018","article-title":"Phage therapy for treatment of virulent Klebsiella pneumoniae infection in a mouse model","volume":"21","author":"Anand","year":"2020","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0112","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.3390\/antibiotics10091048","article-title":"Topically applied bacteriophage to control multi-drug resistant Klebsiella pneumoniae infected wound in a rat model","volume":"10","author":"Fayez","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0113","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13568-021-01181-0","article-title":"Phages from Ganges River curtail in vitro biofilms and planktonic growth of drug resistant Klebsiella pneumoniae in a zebrafish infection model","volume":"11","author":"Sundaramoorthy","year":"2021","journal-title":"AMB Express"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0114","doi-asserted-by":"crossref","first-page":"4200","DOI":"10.1128\/AEM.00526-16","article-title":"In vivo application of bacteriophage as a potential therapeutic agent to control OXA-66-like carbapenemase-producing Acinetobacter baumannii strains belonging to sequence type 357","volume":"82","author":"Jeon","year":"2016","journal-title":"Appl Environ Microbiol"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0115","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12866-019-1443-5","article-title":"Efficacy of bacteriophage treatment against carbapenem-resistant Acinetobacter baumannii in Galleria mellonella larvae and a mouse model of acute pneumonia","volume":"19","author":"Jeon","year":"2019","journal-title":"BMC Microbiol"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0116","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1159\/000486117","article-title":"Phage Abp1 rescues human cells and mice from infection by pan-drug resistant Acinetobacter baumannii","volume":"44","author":"Yin","year":"2017","journal-title":"Cell Physiol Biochem"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0117","doi-asserted-by":"crossref","first-page":"e00424","DOI":"10.1128\/jvi.00467-24","article-title":"In vivo efficacy of phage cocktails against carbapenem resistance Acinetobacter baumannii in the rat pneumonia model","volume":"98","author":"Li","year":"2024","journal-title":"J Virol"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0118","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104045","article-title":"Phage-antibiotic combination is a superior treatment against Acinetobacter baumannii in a preclinical study","volume":"80","author":"Gordillo Altamirano","year":"2022","journal-title":"eBioMedicine"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0119","doi-asserted-by":"crossref","first-page":"946","DOI":"10.3390\/antibiotics10080946","article-title":"Successful intratracheal treatment of phage and antibiotic combination therapy of a multi-drug resistant Pseudomonas aeruginosa murine model","volume":"10","author":"Duplessis","year":"2021","journal-title":"Antibiotics"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0120","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1038\/s41467-024-45785-z","article-title":"Exploiting lung adaptation and phage steering to clear pan-resistant Pseudomonas aeruginosa infections in vivo","volume":"15","author":"Ashworth","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0121","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1007\/s12275-011-1512-4","article-title":"Antibacterial efficacy of lytic Pseudomonas bacteriophage in normal and neutropenic mice models","volume":"49","author":"Tiwari","year":"2011","journal-title":"J Microbiol"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0122","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.trsl.2018.12.002","article-title":"Safety and efficacy of a bacteriophage cocktail in an in vivo model of Pseudomonas aeruginosa sinusitis","volume":"206","author":"Fong","year":"2019","journal-title":"Transl Res"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0123","doi-asserted-by":"crossref","first-page":"6021","DOI":"10.1007\/s00253-015-6492-6","article-title":"In vitro and in vivo antibacterial activity of environmental bacteriophages against Pseudomonas aeruginosa strains from cystic fibrosis patients","volume":"99","author":"Olszak","year":"2015","journal-title":"Appl Microbiol Biotechnol"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0124","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.rvsc.2021.04.010","article-title":"Efficacy assessment of PEV2 phage on Galleria mellonella larvae infected with a Pseudomonas aeruginosa dog otitis isolate","volume":"136","author":"Antoine","year":"2021","journal-title":"Res Vet Sci"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0125","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s12866-018-1234-4","article-title":"The therapeutic potential of bacteriophages targeting Gram-negative bacteria using Galleria mellonella infection model","volume":"18","author":"Manohar","year":"2018","journal-title":"BMC Microbiol"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0126","unstructured":"Emergency Investigational New Drug (EIND) applications for antiviral products. Accessed January 12, 2024. https:\/\/www.fda.gov\/drugs\/investigational-new-drug-ind-application\/emergency-investigational-new-drug-eind-applications-antiviral-products."},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0127","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1039\/D2MA00980C","article-title":"Advancements in bacteriophage therapies and delivery for bacterial infection","volume":"4","author":"Durr","year":"2023","journal-title":"Mater Adv"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0128","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioflm.2024.100245","article-title":"Combination of phages and antibiotics with enhanced killing efficacy against dual-species bacterial communities in a three-dimensional lung epithelial model","volume":"9","author":"Akturk","year":"2025","journal-title":"Biofilm"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0129","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.cmi.2023.01.021","article-title":"Pharmacokinetics\/pharmacodynamics of phage therapy: a major hurdle to clinical translation","volume":"29","author":"Nang","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0130","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/s41591-025-03678-8","article-title":"Personalized inhaled bacteriophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa in cystic fibrosis","volume":"31","author":"Chan","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0131","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2024.11.018","article-title":"Randomized double-blind study on safety and tolerability of TP-102 phage cocktail in patients with infected and non-infected diabetic foot ulcers","volume":"6","author":"Nir-Paz","year":"2025","journal-title":"Med"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0132","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1038\/s41564-024-01733-7","article-title":"Advocating for phage therapy","volume":"9","year":"2024","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0133","unstructured":"NIAID RFA: Centers for accelerating phage therapy (CAPT-CEP). Accessed December 14, 2024. https:\/\/amr.solutions\/2024\/10\/23\/niaid-rfa-centers-for-accelerating-phage-therapy-capt-cep\/."},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0134","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e34333","article-title":"Engineered bacteriophages: a panacea against pathogenic and drug resistant bacteria","volume":"10","author":"Kakkar","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.micpath.2024.107088","article-title":"Phage therapy: a targeted approach to overcoming antibiotic resistance","volume":"197","author":"Olawade","year":"2024","journal-title":"Microb Pathog"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0136","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.tibtech.2022.08.008","article-title":"Approaches for bacteriophage genome engineering","volume":"41","author":"Mahler","year":"2023","journal-title":"Trends Biotechnol"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0137","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2023.1172635","article-title":"Engineering bacteriophages for enhanced host range and efficacy: insights from bacteriophage-bacteria interactions","volume":"14","author":"Jia","year":"2023","journal-title":"Front Microbiol"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0138","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3390\/v10060335","article-title":"Phage genetic engineering using CRISPR\u2013Cas systems","volume":"10","author":"Hatoum-Aslan","year":"2018","journal-title":"Viruses"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0139","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1128\/JB.00747-15","article-title":"Functional analysis of bacteriophage immunity through a type I-E CRISPR-Cas system in Vibrio cholerae and its application in bacteriophage genome engineering","volume":"198","author":"Box","year":"2016","journal-title":"J Bacteriol"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0140","series-title":"Streptococcus pyogenes: basic biology to clinical manifestations","article-title":"The CRISPR-Cas system of Streptococcus pyogenes: function and applications","author":"Varble","year":"2022"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0141","doi-asserted-by":"crossref","first-page":"9504","DOI":"10.1093\/nar\/gku628","article-title":"CRISPR-Cas: an efficient tool for genome engineering of virulent bacteriophages","volume":"42","author":"Martel","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0142","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1021\/acssynbio.6b00388","article-title":"Genome engineering of virulent lactococcal phages using CRISPR-Cas9","volume":"6","author":"Lemay","year":"2017","journal-title":"ACS Synth Biol"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0143","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1093\/nar\/gkab1299","article-title":"Different modes of spacer acquisition by the Staphylococcus epidermidis type III-A CRISPR-Cas system","volume":"50","author":"Aviram","year":"2022","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0144","doi-asserted-by":"crossref","first-page":"e00017","DOI":"10.1128\/mSphere.00040-17","article-title":"A novel Staphylococcus podophage encodes a unique lysin with unusual modular design","volume":"2","author":"Cater","year":"2017","journal-title":"mSphere"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0145","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.coviro.2021.12.003","article-title":"Engineering therapeutic phages for enhanced antibacterial efficacy","volume":"52","author":"Meile","year":"2022","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0146","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nature09929","article-title":"A system for the continuous directed evolution of biomolecules","volume":"472","author":"Esvelt","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0147","doi-asserted-by":"crossref","first-page":"11007","DOI":"10.1093\/nar\/gkz865","article-title":"Retrons and their applications in genome engineering","volume":"47","author":"Simon","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0148","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1038\/s41587-024-02392-z","article-title":"Phage genome engineering with retrons","volume":"43","author":"Osterman","year":"2024","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0149","article-title":"Phage therapy: targeting intestinal bacterial microbiota for the treatment of liver diseases","volume":"5","author":"Fujiki","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0150","doi-asserted-by":"crossref","DOI":"10.1038\/srep41441","article-title":"Microencapsulation with alginate\/CaCO3: a strategy for improved phage therapy","volume":"7","author":"Colom","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0151","doi-asserted-by":"crossref","first-page":"405","DOI":"10.3390\/pharmaceutics17040405","article-title":"Development of inhalable bacteriophage liposomes against Pseudomonas aeruginosa","volume":"17","author":"Sawant","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0152","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0312469","article-title":"Development of phage-containing hydrogel for treating Enterococcus faecalis-infected wounds","volume":"19","author":"Abed","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0153","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1038\/s41467-024-47192-w","article-title":"Phage-specific immunity impairs efficacy of bacteriophage targeting vancomycin resistant Enterococcus in a murine model","volume":"15","author":"Berkson","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0154","doi-asserted-by":"crossref","first-page":"162","DOI":"10.4292\/wjgpt.v8.i3.162","article-title":"Phage therapy: an alternative to antibiotics in the age of multi-drug resistance","volume":"8","author":"Lin","year":"2017","journal-title":"World J Gastrointest Pharmacol Ther"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0155","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.3390\/ijms21051883","article-title":"Bacteriophage-insensitive mutants of antimicrobial-resistant Salmonella enterica are altered in their tetracycline resistance and virulence in Caco-2 intestinal cells","volume":"21","author":"Fong","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0156","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.3390\/ph16121638","article-title":"Phage therapy\u2014challenges, opportunities and future prospects","volume":"16","author":"Zalewska-Pi\u0105tek","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0157","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1038\/s41564-024-01705-x","article-title":"Personalized bacteriophage therapy outcomes for 100 consecutive cases: a multicentre, multinational, retrospective observational study","volume":"9","author":"Pirnay","year":"2024","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0158","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3389\/fphar.2015.00180","article-title":"Unexploited opportunities for phage therapy","volume":"6","author":"Oliveira","year":"2015","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ijantimicag.2025.107640_bib0159","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/cid\/ciy947","article-title":"A systematic and critical review of bacteriophage therapy against multidrug-resistant ESKAPE organisms in humans","volume":"69","author":"El Haddad","year":"2019","journal-title":"Clin Infect Dis"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857925001955?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857925001955?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T23:12:38Z","timestamp":1775517158000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857925001955"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":159,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0924857925001955"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2025.107640","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overcoming antimicrobial resistance: Phage therapy as a promising solution to combat ESKAPE pathogens","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2025.107640","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107640"}}